Triple Moving Average Crossover
Previous Close | 49.56 |
Open | 50.04 |
Bid | 48.07 x 900 |
Ask | 51.43 x 3000 |
Day's Range | 48.75 - 50.24 |
52 Week Range | 30.67 - 54.86 |
Volume | |
Avg. Volume | 514,626 |
Market Cap | 2.977B |
Beta (5Y Monthly) | 1.16 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.41 |
Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.82 |
In this article, we are going to discuss the 15 most suicidal states in America. You can skip our detailed analysis of global suicide statistics, suicide rates in the U.S., financial cost of suicide and biotech companies working to treat mental heath issues and go directly to 5 Most Suicidal States in America. Every year, over […]
Even if it's not a huge purchase, we think it was good to see that Elizabeth Barrett, a Sage Therapeutics, Inc...
CAMBRIDGE, Mass., May 03, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in May:
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 02, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the first quarter ended March 31, 2023.
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the last year, multiple insiders have substantially increased their holdings of Sage Therapeutics, Inc...
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 18, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, May 2, 2023 at 8:00 a.m. ET to review first quarter 2023 financial results and discuss recent business updates.
CAMBRIDGE, Mass., March 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 11:00 a.m. ET.
CAMBRIDGE, Mass., March 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company’s Board of Directors.
Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
CAMBRIDGE, Mass., March 08, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
CAMBRIDGE, Mass., February 28, 2023--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET in Boston, MA.
CAMBRIDGE, Mass., February 22, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE-718 is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction. Multiple clinical studies are ongoing with SAGE-718 across several di
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2022 Earnings Call Transcript February 16, 2023 Operator: Good morning. Welcome to the Sage Therapeutics’ Fourth Quarter and Full-Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage’s website at sagerx.com. This […]
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., February 16, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) and postpartum depression (PPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. William Blair views the acceptance as an important milestone for the company. The analyst believes the granting of priority review, though not surprising, is an incremental positive
CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatme
CAMBRIDGE, Mass., February 02, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Thursday, February 16, 2023 at 8:00 a.m. ET to review fourth quarter and full year 2022 financial results and discuss recent business updates.
XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.